Table 1: Patients demographics.
|
|
Alemtuzumab |
Basiliximab |
Thymoglobulin |
p value |
|
Age |
|
|
|
< 0.0001 |
|
N |
264 |
149 |
236 |
|
|
Sex |
|
|
|
0.0006 |
|
Female |
91 (34.5%) |
54 (36.2%) |
119 (50.4%) |
|
|
Male |
173 (65.5%) |
95 (63.8%) |
117 (49.6%) |
|
|
Race |
|
|
|
0.3546 |
|
Missing |
79 |
57 |
47 |
|
|
White |
83 (44.9%) |
50 (54.3%) |
79 (41.8%) |
|
|
Black/African American |
89 (48.1%) |
37 (40.2%) |
99 (52.4%) |
|
|
Other |
13 (7.0%) |
5 (5.4%) |
11 (5.8%) |
|
Patients demographics, 649 patients were enrolled. Age was significantly higher in group received Basiliximab as expected based on immunosuppressive induction protocol (patients 65 years of age and older). Thymoglobulin induction group has equal female and male distribution when compared to Alemtuzumab and Basiliximab.